Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Science › SpaceX Bonds Weaken, Credit Risk Gauge Worsens On Debt Fears
Science

SpaceX Bonds Weaken, Credit Risk Gauge Worsens On Debt Fears

Bloomberg Markets Wednesday 21 October 2026, 16:43 UTC By Zahra Tayeb and Caleb Mutua 1 min read
Key Points

Bonds SpaceX Bonds Weaken, Credit Risk Gauge Worsens On Debt Fears SpaceX bonds weakened Wednesday after the company posted results that surpassed analysts’ estimates but also said it was investing aggressively, signaling more borrowing could be ahead. Risk premiums for the aerospace and AI company climbed, following widening for the company’s credit derivatives earlier this week. Spreads on SpaceX’s 6.6% notes due in 2046 widened 0.09 percentage point to 2.64 percent points as of 12:35 p.m....

Bonds SpaceX Bonds Weaken, Credit Risk Gauge Worsens On Debt Fears SpaceX bonds weakened Wednesday after the company posted results that surpassed analysts’ estimates but also said it was investing aggressively, signaling more borrowing could be ahead. Risk premiums for the aerospace and AI company climbed, following widening for the company’s credit derivatives earlier this week. Spreads on SpaceX’s 6.6% notes due in 2046 widened 0.09 percentage point to 2.64 percent points as of 12:35 p.m. New York time.
SpaceX (ORG) Credit Risk Gauge Worsens On Debt Fears (ORG) Credit Risk Gauge Worsens On Debt Fears SpaceX (ORG) AI (ORG) New York (LOCATION)
Originally published by Bloomberg Markets Read original →

Related Stories

Controversial US-backed vaccine trial in African newborns halted

Hepatitis B study in Guinea-Bissau that was to be funded by CDC and that drew global backlash ‘will not move forward’The US-backed hepatitis B vaccine trial in African newborns that drew global backlash was halted, the lead researcher said on Wednesday. It is “now clear” that the study “will not move forward in Guinea-Bissau”, Frederik Schaltz-Buchholzer, a Danish researcher, wrote on LinkedIn, adding, “we were not given the necessary governmental approval.”

The Guardian UK 30m ago

Controversial US-backed vaccine trial in African newborns halted

Hepatitis B study in Guinea-Bissau that was to be funded by CDC and that drew global backlash ‘will not move forward’The US-backed hepatitis B vaccine trial in African newborns that drew global backlash was halted, the lead researcher said on Wednesday. It is “now clear” that the study “will not move forward in Guinea-Bissau”, Frederik Schaltz-Buchholzer, a Danish researcher, wrote on LinkedIn, adding, “we were not given the necessary governmental approval.”

The Guardian World 30m ago

Controversial US-backed vaccine trial in African newborns halted

Hepatitis B study in Guinea-Bissau that was to be funded by CDC and that drew global backlash ‘will not move forward’The US-backed hepatitis B vaccine trial in African newborns that drew global backlash was halted, the lead researcher said on Wednesday. It is “now clear” that the study “will not move forward in Guinea-Bissau”, Frederik Schaltz-Buchholzer, a Danish researcher, wrote on LinkedIn, adding, “we were not given the necessary governmental approval.”

The Guardian Health 30m ago

Man with a PhD and Nobel-cited research has sent out 2,300 applications yet cannot land a job

Man with a PhD and Nobel-cited research has sent out 2,300 applications yet cannot land a job Despite unemployment hovering between 3.5 percent and 4.3 percent over the past three years, applicants say finding work remains difficult - Bookmark - CommentsGo to comments Become an Independent member to bookmark this article Already a member? Log in A Princeton University graduate, whose research was cited by the Nobel committee, says he has applied for more than 2,300 jobs since earning his...

The Independent World 33m ago